Are you an experienced PhD in Biochemistry? Do you have experience with enzymes? Do you want to call San Diego home? If so, you should take a close look at this role.

A biochemist with enzyme purification experience. Bioprocess development role. Troubleshoot methods and bioprocesses for how to purify enzymes and get more yield. Room to grow to Principal Scientist or Research Fellow. PhD in Biochemistry absolutely required.

You must have PhD in biochemistry plus 5 years of relevant experience in protein purification. Requires experience in downstream process development as it relates to protein recovery and purification. Prior experience in chromatrography procedures to remove product related impurities.

If you are a talented Biochemistry professional and you are interested in joining a reputable, growing firm, please e-mail your resume ALONG WITH A DETAILED COVER LETTER that explains why your background matches this position to btsan081010b@jobsearchdigest.com.

 

Robin Ryan has developed a career counseling practice where she offers both in-person and telephone consultations to assist clients nationwide. She has over 15 years of expertise helping people in finance advance their careers. A trusted adviser, Robin offers resume writing and career consulting services helping with resumes, interviews, salary negotiation, career changes, and promotions.

Robin Ryan has appeared on Oprah, Dr Phil, NBC Nightly News, CNN, CNBC, and Fox News. Robin’s advice and articles have appeared in Money, Newsweek, Fortune, Business Week, the Wall Street Journal, USA Today, New York Times, and many others. She is the best selling author of: 60 Seconds & You’re Hired!; Winning Resumes; Winning Cover Letters; Soaring On Your Strengths; and What to Do with the Rest of Your Life.

 

Although States like to put the marketing spin on their Biotech Jobs activity, there is still one major hub when it comes to Biotechnology - Northern California.

San Francisco, Mountain View, Palo Alto, Santa Clara and other cities are home to many young Biotech firms that are raking in the angel and venture capital investments. In 2006, according to a CONNECT and San Diego Institute for Policy Research study, Northern California pulled in 36% of the Nation’s VC in 2006 and 2007 ($9.6 billion and $11 billion, respectively).  In the first 6 months of 2008, “Nor Cal” took 41% of the venture capital raised ($5.6 billion) in the US.

It is interesting to note that, despite massive amounts of venture capital, the ratio of life science start ups in Northern California is much smaller than San Diego/Southern California. When it comes to start ups, San Francisco sees a whopping 90% of its new tech firm activity in communications, software and computers/electronics.

So, where is all this VC going if not to biotech start ups? The answer is found in investing strategy. The vast majority of US venture capital, in fact 78%, went to companies in expansion stage or later. It seems, although considered a sexy investment, seed round and early stage companies garner much less attention and money from the investment community.

 

A recent study released by CONNECT and the San Diego Institute for Policy Research revealed the life science venture capital flow in 2008 so far.

In Q2, 76 new tech start-up were created (13% of California’s health tech activity). A hefty 27.6% of all San Diego’s start-up technology companies were in Pharma, Biotech or Medical. These industries tied with software for the biggest number of new starts.

From a venture capital standpoint, Biotech Beach is raking in the cash. While California took over 50% of the Nation’s venture capital investment in Q2 (3.9  billion), San Diego took in about 10% of that money. And Biotechnology accounted for 32% of dollars invested in San Diego based companies, with the average deal exceeding $10 million.

An interesting finding of the study is that typically the number of start-up in California increases dramatically in the second half of the year - with Q4 tripling Q1 activity. Now, that is something to look forward to.

 

A pure biochemist with industry experience, including experience with enzymes, not just antibodies.  Bioprocess development role. Troubleshoot methods and bioprocesses for how to purify enzymes and get more yield. Room to grow to Principal Scientist or Research Fellow. PhD in Biochemistry absolutely required.

If you are a talented PhD in Biochemistry professional and you are interested in joining a reputable, growing firm, please check out the biotechnology job listings on Biotech Jobs Digest.

 

Check out this highly recommended presentation. A slide show of a presentation given to students with a general introduction to the business of biotechnology. The material is drawn from the book Building Biotechnology by Yali Friedman, Ph.D.

 

According to the Wall Street Journal Online, Eli Lilly is on its way to acquiring ImClone for more than $6 billion USD. To this point, ImClone’s Carl Icahn has simply referred to the potential suitor as a “large pharma company.” The rumored price is $70 per share and ImClone closed today at $65.35 per share.  The offer price is significantly higher than the $62 per share offer from Bristol-Myers, who owns about 15% of ImClone.

Althought the deal is far from done, the combination of the two firms should put ImClone’s projects on stable ground and present many new biotech job opportunities as Lilly positions for a solid return on their investment.